P07.02 Trials of a personalized peptide vaccine (ITK-1) for patients with recurrent or progressive glioblastoma (GBM)

Immunotherapy trials for glioblastoma (GBM) have some effects but the efficacy was limited, some because of the low immunogenicity and diverse antigens for GBMs. Personalized selection of suitable peptides for patients is one way to conquer this problem. We conducted serial series of clinical trials...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Fujimaki, T., Itoh, K., Terasaki, M., Narita, Y., Arakawa, Y., Sugiyama, K., Nishikawa, R., Aoki, T., Kumabe, T., Nagane, M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2017
Pynciau:
POSTER PRESENTATIONS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464231/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.187
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg